Department of Biological Chemistry, University of Athens Medical School, Athens, Greece.
Curr Med Chem. 2012;19(16):2555-71. doi: 10.2174/092986712800492986.
Cardiovascular disease (CVD) remains the leading cause of premature death in patients with chronic kidney disease (CKD). Recent evidence suggests that the interaction of "classic" and "non-classic" cardiovascular risk factors is an important contributor in excessive and accelerated CVD in patients with CKD. Indeed, the imposing cardiovascular morbidity and mortality of CKD patients corresponds to a significant extent in endothelial dysfunction, inflammation, oxidative stress, vascular calcification and volume overload. In addition, the kidney's function decline is independently associated with CVD in patients with chronic kidney disease. Currently, there is a growing interest in the role of new biomarkers that are closely correlated with CVD in CKD population. In current review, we summarize the so far acquired knowledge of the most promising biomarkers and we discuss the major clinical correlations of novel risk factors and new biomarkers of CVD in CKD patients, their predictive value for future cardiovascular events and their use in the treatment monitoring of this population.
心血管疾病(CVD)仍然是慢性肾脏病(CKD)患者过早死亡的主要原因。最近的证据表明,“经典”和“非经典”心血管危险因素的相互作用是 CKD 患者 CVD 过度和加速发展的重要因素。事实上,CKD 患者沉重的心血管发病率和死亡率在很大程度上与内皮功能障碍、炎症、氧化应激、血管钙化和容量超负荷有关。此外,肾脏功能下降与 CKD 患者的 CVD 独立相关。目前,人们对与 CKD 人群 CVD 密切相关的新型生物标志物的作用越来越感兴趣。在当前的综述中,我们总结了迄今为止获得的最有前途的生物标志物的知识,并讨论了 CKD 患者中新的 CVD 危险因素和生物标志物的主要临床相关性、它们对未来心血管事件的预测价值以及它们在该人群治疗监测中的应用。